Use of replicating oncolytic adenoviruses in combination therapy for cancer.
about
Oncolytic Adenovirus: Strategies and Insights for Vector Design and Immuno-Oncolytic ApplicationsOncolytic virotherapy of canine and feline cancerGene medicine for cancer treatment: commercially available medicine and accumulated clinical data in ChinaOncolytic Virus-Based Immunotherapies for Hepatocellular Carcinoma.Synergistic antitumor effects of CDK inhibitor SNS‑032 and an oncolytic adenovirus co‑expressing TRAIL and Smac in pancreatic cancerEnhanced therapeutic efficacy by simultaneously targeting two genetic defects in tumors.Upregulation of Coxsackie Adenovirus Receptor Sensitizes Cisplatin-Resistant Lung Cancer Cells to CRAd-Induced InhibitionEnvelope targeting: hemagglutinin attachment specificity rather than fusion protein cleavage-activation restricts Tupaia paramyxovirus tropism.Hyaluronidase expression by an oncolytic adenovirus enhances its intratumoral spread and suppresses tumor growth.Indole-3-carbinol (I3C) increases apoptosis, represses growth of cancer cells, and enhances adenovirus-mediated oncolysisReduction of nontarget infection and systemic toxicity by targeted delivery of conditionally replicating viruses transported in mesenchymal stem cellsCombinatory cytotoxic effects produced by E1B-55kDa-deleted adenoviruses and chemotherapeutic agents are dependent on the agents in esophageal carcinoma.Enhanced delivery of mda-7/IL-24 using a serotype chimeric adenovirus (Ad.5/3) in combination with the Apogossypol derivative BI-97C1 (Sabutoclax) improves therapeutic efficacy in low CAR colorectal cancer cellsA steep radioiodine dose response scalable to humans in sodium-iodide symporter (NIS)-mediated radiovirotherapy for prostate cancer.Progress in gene therapy for prostate cancerOncolytic adenovirus armed with IL-24 inhibits the growth of breast cancer in vitro and in vivo.Targeted cancer gene therapy using a hypoxia inducible factor dependent oncolytic adenovirus armed with interleukin-4Strategies and developments of immunotherapies in osteosarcomaDownregulation of Mcl-1 synergizes the apoptotic response to combined treatment with cisplatin and a novel fiber chimeric oncolytic adenovirusSelective killing of Smad4-negative tumor cells via a designed repressor strategyThe effects of radiation on antitumor efficacy of an oncolytic adenovirus vector in the Syrian hamster modelYB-1 dependent oncolytic adenovirus efficiently inhibits tumor growth of glioma cancer stem like cells.Construction of an MUC-1 promoter driven, conditionally replicating adenovirus that expresses the sodium iodide symporter for gene therapy of breast cancer.Armed replicating adenoviruses for cancer virotherapy.Stem cells as delivery vehicles for oncolytic adenoviral virotherapy.Oncolytic adenovirus encoding tumor necrosis factor-related apoptosis inducing ligand (TRAIL) inhibits the growth and metastasis of triple-negative breast cancer.Homoharringtonine acts synergistically with SG235-TRAIL, a conditionally replicating adenovirus, in human leukemia cell lines.Combining conditionally replicating adenovirus-mediated gene therapy with chemotherapy: a novel antitumor approach.Conditionally replicating adenoviruses carrying mda-7/IL-24 for cancer therapy.Recent developments in oncolytic adenovirus-based immunotherapeutic agents for use against metastatic cancers.Evolution of oncolytic viruses: novel strategies for cancer treatment.Chemotherapy and Oncolytic Virotherapy: Advanced Tactics in the War against Cancer.Synergistic antitumor activity of triple-regulated oncolytic adenovirus with VSTM1 and daunorubicin in leukemic cells.Expression of the coxsackie adenovirus receptor in neuroendocrine lung cancers and its implications for oncolytic adenoviral infection.A conditionally replicating adenovirus carrying interleukin-24 sensitizes melanoma cells to radiotherapy via apoptosis.GALV expression enhances the therapeutic efficacy of an oncolytic adenovirus by inducing cell fusion and enhancing virus distribution.Improved killing of human high-grade glioma cells by combining ionizing radiation with oncolytic parvovirus H-1 infection.Oncolytic adenovirus armed with human papillomavirus E2 gene in combination with radiation demonstrates synergistic enhancements of antitumor efficacy.A probasin promoter, conditionally replicating adenovirus that expresses the sodium iodide symporter (NIS) for radiovirotherapy of prostate cancer.Oncolytic adenovirus expressing interleukin-18 induces significant antitumor effects against melanoma in mice through inhibition of angiogenesis.
P2860
Q26776553-FE84116D-408D-416B-9C3B-5E8BF09F5CACQ27008306-D0F72854-04BA-49C3-9B32-6F2A5EF660D2Q33516121-AFB07C48-A72F-45E5-AF09-CBFF6E74BACBQ33635033-F1B56880-09A9-4122-ABA2-0C893087F118Q33702030-C870E186-17F1-4CC7-AE87-FB5E7EF19E34Q33713001-A2353FB1-B58C-47CC-A6E8-B3C9F9929E46Q33820871-45920270-1D6D-4E26-8148-FE8F96FBB6A9Q33911962-8CAACD65-876D-433B-B9E2-E8189690D8A1Q34025129-4F6D0AF4-3831-4090-B02F-B8F8257D6958Q34028482-DACDA4B1-C0F6-4900-BE8B-29CAED64F946Q34154904-4620F6CC-63CD-4256-9DFE-C7DA2C201ED5Q34238784-7F43E80F-AC46-4A99-9B46-8848799292B4Q35587169-F71B9CF7-E7AE-40C9-994D-51127BCB2A79Q36403691-FCF047B4-7654-42BE-8F0D-91113404623BQ36406911-79C5A385-2E78-418B-95C2-EF98B267B80FQ36437378-E670D4D3-1720-42C0-953D-E3F7473FAFB7Q36488714-C75ABB4E-1009-41C4-AED3-F5244987AD28Q36503128-FC7CF4C5-A682-4738-ADD9-719D6A45FBCCQ36642630-FB768D95-EA1A-418D-9D23-1357B1684943Q36923812-EA1C3BFC-8486-4B9D-BFCD-AB1350E5C3D9Q37185117-F7E64F0B-E06C-4B53-8A1C-A012917727CDQ37360181-DFCB3AA7-6B80-499B-81D3-DD9E9BF413E7Q37360204-59FF3D6E-D946-4C91-8058-D952641774CAQ37386616-04A7CDC4-674B-43CE-B91A-8711C972418FQ37466041-49B95906-4581-4959-A05D-C3E181A56C1CQ37586895-E88AAAEC-A3C6-43B0-B908-0B292FAF73E0Q37729281-3AB47D7D-F62C-4C7B-8F5B-DB2D5D218D82Q37867584-B966DAF9-5203-4C87-8DF1-5E1EBE694FD1Q37945288-8D100C63-E144-40BA-9E96-905478AAC969Q38073096-82FFE36B-E710-4C83-BCC7-DD5160C9C60EQ38159802-8D304AA3-7B0A-4BEA-8ECE-7CF9307EF59AQ38223419-35672BE6-6EF5-4E47-BE12-29E562079E75Q38754849-AECD6E5D-2ECF-4B15-A6A8-C2B4599EFE2FQ39235688-B53DED8B-6696-463E-AD26-6F56C9D10977Q39336014-ED39A044-41DD-4DCD-90B6-EB1134B90292Q39437927-C0309EC5-64C7-4E04-BDBB-B34A9DCA0E6CQ39442081-E3837993-C822-4040-9F4A-69EC6EA79BC3Q39488257-0C82A6C5-55B9-4B9B-A5E8-6DEEEF51A206Q39709581-378D6FB0-8290-407D-BB77-93794D160A60Q39842445-936C93E9-77E9-4F22-A940-685DA566991B
P2860
Use of replicating oncolytic adenoviruses in combination therapy for cancer.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Use of replicating oncolytic adenoviruses in combination therapy for cancer.
@ast
Use of replicating oncolytic adenoviruses in combination therapy for cancer.
@en
type
label
Use of replicating oncolytic adenoviruses in combination therapy for cancer.
@ast
Use of replicating oncolytic adenoviruses in combination therapy for cancer.
@en
prefLabel
Use of replicating oncolytic adenoviruses in combination therapy for cancer.
@ast
Use of replicating oncolytic adenoviruses in combination therapy for cancer.
@en
P2093
P1476
Use of replicating oncolytic adenoviruses in combination therapy for cancer.
@en
P2093
Dawn E Post
Fadlo R Khuri
Roland L Chu
P304
P356
10.1158/1078-0432.CCR-0349-03
P407
P577
2004-08-01T00:00:00Z